- Home
- TC vs NRSN Comparison
TC vs NRSN Comparison
Compare TC & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | NRSN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | China | Israel |
| Employees | N/A | 15 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 24.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TC | NRSN |
|---|---|---|
| Price | $10.51 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.7K | ★ 187.1K |
| Earning Date | 03-26-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.63 |
| 52 Week High | $19.99 | $2.60 |
Technical Indicators
Market Signals| Indicator | TC | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 42.11 |
| Support Level | $8.93 | $0.66 |
| Resistance Level | $11.00 | $1.30 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 38.86 | 50.35 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.